Literature DB >> 21161712

Different profiles of Alzheimer's disease cerebrospinal fluid biomarkers in controls and subjects with subjective memory complaints.

Anna Antonell1, Juan Fortea, Lorena Rami, Beatriz Bosch, Mircea Balasa, Raquel Sánchez-Valle, Alex Iranzo, José Luis Molinuevo, Albert Lladó.   

Abstract

Cerebrospinal fluid (CSF) biomarkers, such as Aβ(42), total-tau and phosphorylated-tau(181) reflect neuropathological changes of Alzheimer's disease (AD). We studied these biomarkers in 24 controls and 19 subjects with subjective memory complaints, and we distinguished different CSF profiles: normal (group 1, 55.8%), only pathologic Aβ(42) (group 2, 27.9%), pathologic Aβ(42) plus pathologic total-tau and/or phosphorylated-tau(181) (group 3, 7%), and only pathologic total-tau and phosphorylated-tau(181) (group 4, 9.3%). Group 2 could represent an earlier phase of preclinical AD than group 3, and group 4 an unknown etiology.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21161712     DOI: 10.1007/s00702-010-0534-0

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN: 0300-9564            Impact factor:   3.575


  19 in total

1.  CSF biomarkers predict a more malignant outcome in Alzheimer disease.

Authors:  A K Wallin; K Blennow; H Zetterberg; E Londos; L Minthon; O Hansson
Journal:  Neurology       Date:  2010-05-11       Impact factor: 9.910

2.  Neuropathology of nondemented aging: presumptive evidence for preclinical Alzheimer disease.

Authors:  Joseph L Price; Daniel W McKeel; Virginia D Buckles; Catherine M Roe; Chengjie Xiong; Michael Grundman; Lawrence A Hansen; Ronald C Petersen; Joseph E Parisi; Dennis W Dickson; Charles D Smith; Daron G Davis; Frederick A Schmitt; William R Markesbery; Jeffrey Kaye; Roger Kurlan; Christine Hulette; Brenda F Kurland; Roger Higdon; Walter Kukull; John C Morris
Journal:  Neurobiol Aging       Date:  2009-04-18       Impact factor: 4.673

3.  Decreased cerebrospinal fluid Abeta(42) correlates with brain atrophy in cognitively normal elderly.

Authors:  Anne M Fagan; Denise Head; Aarti R Shah; Daniel Marcus; Mark Mintun; John C Morris; David M Holtzman
Journal:  Ann Neurol       Date:  2009-02       Impact factor: 10.422

4.  APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging.

Authors:  John C Morris; Catherine M Roe; Chengjie Xiong; Anne M Fagan; Alison M Goate; David M Holtzman; Mark A Mintun
Journal:  Ann Neurol       Date:  2010-01       Impact factor: 10.422

5.  Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults.

Authors:  Anne M Fagan; Catherine M Roe; Chengjie Xiong; Mark A Mintun; John C Morris; David M Holtzman
Journal:  Arch Neurol       Date:  2007-01-08

6.  Cerebrospinal fluid biomarkers in Alzheimer's disease families with PSEN1 mutations.

Authors:  Juan Fortea; Albert Lladó; Beatriz Bosch; Anna Antonell; Rafael Oliva; Jose Luis Molinuevo; Raquel Sánchez-Valle
Journal:  Neurodegener Dis       Date:  2011-01-05       Impact factor: 2.977

7.  Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade.

Authors:  Clifford R Jack; David S Knopman; William J Jagust; Leslie M Shaw; Paul S Aisen; Michael W Weiner; Ronald C Petersen; John Q Trojanowski
Journal:  Lancet Neurol       Date:  2010-01       Impact factor: 44.182

8.  CSF tau/Abeta42 ratio for increased risk of mild cognitive impairment: a follow-up study.

Authors:  G Li; I Sokal; J F Quinn; J B Leverenz; M Brodey; G D Schellenberg; J A Kaye; M A Raskind; J Zhang; E R Peskind; T J Montine
Journal:  Neurology       Date:  2007-08-14       Impact factor: 9.910

9.  Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study.

Authors:  Pieter Jelle Visser; Frans Verhey; Dirk L Knol; Philip Scheltens; Lars-Olof Wahlund; Yvonne Freund-Levi; Magda Tsolaki; Lennart Minthon; Asa K Wallin; Harald Hampel; Katharina Bürger; Tuula Pirttila; Hilkka Soininen; Marcel Olde Rikkert; Marcel M Verbeek; Luiza Spiru; Kaj Blennow
Journal:  Lancet Neurol       Date:  2009-06-10       Impact factor: 44.182

10.  Frequent amyloid deposition without significant cognitive impairment among the elderly.

Authors:  Howard Jay Aizenstein; Robert D Nebes; Judith A Saxton; Julie C Price; Chester A Mathis; Nicholas D Tsopelas; Scott K Ziolko; Jeffrey A James; Beth E Snitz; Patricia R Houck; Wenzhu Bi; Ann D Cohen; Brian J Lopresti; Steven T DeKosky; Edythe M Halligan; William E Klunk
Journal:  Arch Neurol       Date:  2008-11
View more
  11 in total

1.  Plasma miR-34a-5p and miR-545-3p as Early Biomarkers of Alzheimer's Disease: Potential and Limitations.

Authors:  Marta Cosín-Tomás; Anna Antonell; Albert Lladó; Daniel Alcolea; Juan Fortea; Mario Ezquerra; Albert Lleó; Maria José Martí; Mercè Pallàs; Raquel Sanchez-Valle; José Luís Molinuevo; Coral Sanfeliu; Perla Kaliman
Journal:  Mol Neurobiol       Date:  2016-09-08       Impact factor: 5.590

2.  Altered Blood Gene Expression of Tumor-Related Genes (PRKCB, BECN1, and CDKN2A) in Alzheimer's Disease.

Authors:  Anna Antonell; Albert Lladó; Raquel Sánchez-Valle; Coral Sanfeliu; Teresa Casserras; Lorena Rami; Cristina Muñoz-García; Adrià Dangla-Valls; Mircea Balasa; Patricia Boya; Susana G Kalko; José Luis Molinuevo
Journal:  Mol Neurobiol       Date:  2015-10-28       Impact factor: 5.590

Review 3.  CSF biomarkers for amyloid and tau pathology in Alzheimer's disease.

Authors:  Hanna Rosenmann
Journal:  J Mol Neurosci       Date:  2011-11-05       Impact factor: 3.444

4.  Cerebral amyloid angiopathy in Down syndrome and sporadic and autosomal-dominant Alzheimer's disease.

Authors:  María Carmona-Iragui; Mircea Balasa; Bessy Benejam; Daniel Alcolea; Susana Fernández; Laura Videla; Isabel Sala; María Belén Sánchez-Saudinós; Estrella Morenas-Rodriguez; Roser Ribosa-Nogué; Ignacio Illán-Gala; Sofía Gonzalez-Ortiz; Jordi Clarimón; Frederick Schmitt; David K Powell; Beatriz Bosch; Albert Lladó; Michael S Rafii; Elizabeth Head; José Luis Molinuevo; Rafael Blesa; Sebastián Videla; Alberto Lleó; Raquel Sánchez-Valle; Juan Fortea
Journal:  Alzheimers Dement       Date:  2017-04-29       Impact factor: 21.566

Review 5.  Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry.

Authors:  Piotr Lewczuk; Peter Riederer; Sid E O'Bryant; Marcel M Verbeek; Bruno Dubois; Pieter Jelle Visser; Kurt A Jellinger; Sebastiaan Engelborghs; Alfredo Ramirez; Lucilla Parnetti; Clifford R Jack; Charlotte E Teunissen; Harald Hampel; Alberto Lleó; Frank Jessen; Lidia Glodzik; Mony J de Leon; Anne M Fagan; José Luis Molinuevo; Willemijn J Jansen; Bengt Winblad; Leslie M Shaw; Ulf Andreasson; Markus Otto; Brit Mollenhauer; Jens Wiltfang; Martin R Turner; Inga Zerr; Ron Handels; Alexander G Thompson; Gunilla Johansson; Natalia Ermann; John Q Trojanowski; Ilker Karaca; Holger Wagner; Patrick Oeckl; Linda van Waalwijk van Doorn; Maria Bjerke; Dimitrios Kapogiannis; H Bea Kuiperij; Lucia Farotti; Yi Li; Brian A Gordon; Stéphane Epelbaum; Stephanie J B Vos; Catharina J M Klijn; William E Van Nostrand; Carolina Minguillon; Matthias Schmitz; Carla Gallo; Andrea Lopez Mato; Florence Thibaut; Simone Lista; Daniel Alcolea; Henrik Zetterberg; Kaj Blennow; Johannes Kornhuber
Journal:  World J Biol Psychiatry       Date:  2017-10-27       Impact factor: 4.132

Review 6.  Exercise-Related Changes of Networks in Aging and Mild Cognitive Impairment Brain.

Authors:  Pei Huang; Rong Fang; Bin-Yin Li; Sheng-Di Chen
Journal:  Front Aging Neurosci       Date:  2016-03-07       Impact factor: 5.750

7.  CSF glial biomarkers YKL40 and sTREM2 are associated with longitudinal volume and diffusivity changes in cognitively unimpaired individuals.

Authors:  Carles Falcon; Gemma C Monté-Rubio; Oriol Grau-Rivera; Marc Suárez-Calvet; Raquel Sánchez-Valle; Lorena Rami; Beatriz Bosch; Christian Haass; Juan Domingo Gispert; José Luis Molinuevo
Journal:  Neuroimage Clin       Date:  2019-04-01       Impact factor: 4.881

8.  sTREM2 cerebrospinal fluid levels are a potential biomarker for microglia activity in early-stage Alzheimer's disease and associate with neuronal injury markers.

Authors:  Marc Suárez-Calvet; Gernot Kleinberger; Miguel Ángel Araque Caballero; Matthias Brendel; Axel Rominger; Daniel Alcolea; Juan Fortea; Alberto Lleó; Rafael Blesa; Juan Domingo Gispert; Raquel Sánchez-Valle; Anna Antonell; Lorena Rami; José L Molinuevo; Frederic Brosseron; Andreas Traschütz; Michael T Heneka; Hanne Struyfs; Sebastiaan Engelborghs; Kristel Sleegers; Christine Van Broeckhoven; Henrik Zetterberg; Bengt Nellgård; Kaj Blennow; Alexander Crispin; Michael Ewers; Christian Haass
Journal:  EMBO Mol Med       Date:  2016-05-02       Impact factor: 12.137

9.  Structural Connectivity Alterations Along the Alzheimer's Disease Continuum: Reproducibility Across Two Independent Samples and Correlation with Cerebrospinal Fluid Amyloid-β and Tau.

Authors:  Alan Tucholka; Oriol Grau-Rivera; Carles Falcon; Lorena Rami; Raquel Sánchez-Valle; Albert Lladó; Juan Domingo Gispert; José Luis Molinuevo
Journal:  J Alzheimers Dis       Date:  2018       Impact factor: 4.472

10.  Synergistic effects of quercetin and regular exercise on the recovery of spatial memory and reduction of parameters of oxidative stress in animal model of Alzheimer's disease.

Authors:  Amin Molaei; Homeira Hatami; Gholamreza Dehghan; Reihaneh Sadeghian; Nazli Khajehnasiri
Journal:  EXCLI J       Date:  2020-05-08       Impact factor: 4.068

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.